SYDNEY, June 2, 2022 – (ACN Newswire) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, has sponsored expert panels at the Pre-ASCO China Summit 2022 bringing together leaders in oncology drug development in China and the US. The Pre-ASCO series was watched by more than 20,000 people globally.
The Novotech sponsored Summit sessions are:
– Go/No Go Decisions Based on Early Phase Oncology Trials – Watch Here https://tinyurl.com/novotech-webinars
– Development and Regulatory Strategy for China & US – Watch Here https://tinyurl.com/novotech-whitepapers
China offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KOLs.
– According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://tinyurl.com/novotech-whitepapers
– Over the past 5 years, growth of oncology trials (CAGR of 25%) in China outpaced other countries.
– This growth was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immuno-oncology, and leadership in cell therapy
– China also recorded the largest number of new trials, followed by the US. In China, the number of new trials doubled during …